Beta-Blocker Therapy on Blood Pressure in Subclinical Hyperthyroidism: A Retrospective Observational Study

This study aimed to investigate the effect of beta- blocker therapy on blood pressure in patients with subclinical hyperthyroidism and to elucidate the potential benefits of this treatment approach. This retrospective observational cohort study included 56 hypertensive patients with subclinical hyperthyroidism who received beta-blocker therapy. Patient data, including demographic characteristics, thyroid function tests, and blood pressure measurements, were collected from medical records and evaluated using statistical analysis with SPSS Statistics software. The cohort of hypertensive patients included 35 patients with uncontrolled blood pressure and 21 newly diagnosed patients, with a total average age of 55 and 73.2% of them being female. In newly diagnosed and uncontrolled hypertensive patients, TSH levels were below the average, and T3 levels were high (p<0.001). Significant reductions in systolic and diastolic blood pressure were observed in both groups after beta- blocker therapy (p<0.001). The most significant decrease in blood pressure in beta-blocker therapy occurred in newly diagnosed hypertensive patients, with an average decrease of 37.85 mmHg. Additionally, a significant reduction in the number of antihypertensive medications was observed in patients receiving beta-blocker therapy (p<0.001). In conclusion, our study demonstrates the positive effects of beta-blocker therapy on blood pressure control in patients with subclinical hyperthyroidism. Particularly, the significant decrease in blood pressure in newly diagnosed hypertensive patients indicates the potential of beta-blockers as a preferred treatment option. This study highlights the necessity of a causal approach in treating hypertension with thyroid disorders. However, considering the limitations of the study design, further comprehensive research is needed to confirm these findings.